Sotagliflozin for Cardiotoxicity
(SPARTACUS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.
Who Is on the Research Team?
Santos-Gallego, MD
Principal Investigator
Icahn School of Medicine at Mount Sinai
Carlos G Santos-Gallego, MD
Principal Investigator
Icahn School of Medicine at Mount Sinai
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Sotagliflozin 400mg per day or a matching placebo to prevent anthracycline-related cardiotoxicity
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments of cardiac function and biomarkers
What Are the Treatments Tested in This Trial?
Interventions
- Sotagliflozin
How Is the Trial Designed?
2
Treatment groups
Active Control
Placebo Group
Sotagliflozin 400mg per day orally
Matching Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Icahn School of Medicine at Mount Sinai
Lead Sponsor
American Heart Association
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.